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Background: While large-scale cancer genomic projects are comprehensively characterizing the mutational
spectrum of various cancers, so far little attention has been devoted to either define the antigenicity of these
mutations or to characterize the immune responses they elicit. Here we present a strategy to characterize the
immunophenotypes and the antigen-ome of human colorectal cancer.
Results: We apply our strategy to a large colorectal cancer cohort (n = 598) and show that subpopulations of
tumor-infiltrating lymphocytes are associated with distinct molecular phenotypes. The characterization of the
antigenome shows that a large number of cancer-germline antigens are expressed in all patients. In contrast,
neo-antigens are rarely shared between patients, indicating that cancer vaccination requires individualized strategy.
Analysis of the genetic basis of the tumors reveals distinct tumor escape mechanisms for the patient subgroups.
Hypermutated tumors are depleted of immunosuppressive cells and show upregulation of immunoinhibitory molecules.
Non-hypermutated tumors are enriched with immunosuppressive cells, and the expression of immunoinhibitors and
MHC molecules is downregulated. Reconstruction of the interaction network of tumor-infiltrating lymphocytes and
immunomodulatory molecules followed by a validation with 11 independent cohorts (n = 1,945) identifies BCMA as a
novel druggable target. Finally, linear regression modeling identifies major determinants of tumor immunogenicity,
which include well-characterized modulators as well as a novel candidate, CCR8, which is then tested in an orthologous
immunodeficient mouse model.
Conclusions: The immunophenotypes of the tumors and the cancer antigenome remain widely unexplored, and our
findings represent a step toward the development of personalized cancer immunotherapies.Background
Recent studies using large cohorts and next-generation
sequencing (NGS) technologies are providing a wealth of
information and have revealed the genomic landscapes
of common human cancers [1]. But so far little attention
has been devoted to either define the cancer antigen-
ome (that is, the repertoire of the tumor antigens) or to* Correspondence: zlatko.trajanoski@i-med.ac.at
†Equal contributors
1Biocenter, Division of Bioinformatics, Medical University of Innsbruck, Innrain
80, 6020 Innsbruck, Austria
Full list of author information is available at the end of the article
© 2015 Angelova et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.elucidate the immune responses they elicit. This know-
ledge could be exploited for gaining mechanistic insights
into tumor progression and for the development of can-
cer immunotherapies.
Several types of immunotherapies have been shown to
have great clinical impact, including adoptive T-cell
transfer therapy, cellular vaccines, and checkpoint block-
ade inhibitors, such as the FDA-approved anti-CTLA4
monoclonal antibody (ipilimumab) and antibodies that
block signaling through PD-1 and PD-L1 [2,3]. However,
in cancer patients responding to immunotherapy it isral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gression and the elucidation of the cancer antigenome is
thus an important requirement for identifying antigens
which induce an adaptive immune response [4]. For ex-
ample, a recent study described a screening platform to
detect neo-antigen-specific CD4+ T cells [5] based on
exome and RNA sequencing of the tumor followed by
peptide synthesis and co-culture of neo-antigen-loaded
B cells and CD4+ T cells. Furthermore, the identification
of highly immunogenic tumor antigens is a prerequisite
for developing personalized cancer vaccines as shown in
a proof-of-concept study that demonstrated in a mouse
model that a therapeutic pipeline based on NGS ana-
lysis, neo-antigen prediction and selection, and peptide
synthesis followed by vaccination is feasible [6]. Relevance
of this type of whole exome-based analysis in human can-
cer has been subsequently shown in melanoma [7].
Without doubt, given the exciting development of
these immunotherapeutic strategies, the importance and
clinical relevance of intratumoral immune landscapes
and cancer antigenomes is becoming increasingly appre-
ciated. In a seminal paper, epitope prediction algorithms
were used to identify candidate tumor antigens [8]. Only
recently, the first attempt to explore genomic data was
performed by carrying out meta-analysis for several can-
cers and it could be shown that neo-antigens were asso-
ciated with increased patient survival [9]. However, the
number of subjects for individual cancer types was rela-
tively small (515 patients for 6 different tumor sites) and
did not allow analysis for specific cancer subtypes (for
example, microsatellite instable (MSI) or microsatellite
stable (MSS) tumors in colorectal cancer (CRC) patients).
Moreover, since the expression of only three immune
genes was assessed, tumor-infiltrating lymphocytes (TILs)
were completely undefined. Therefore, the adaptive im-
mune response remained elusive.
In order to comprehensively characterize the antige-
nicity and immunogenicity of human CRC, we devel-
oped an analytical strategy and examined genomic data
sets from The Cancer Genome Atlas (TCGA; n = 598)
[10]. We first defined a compendium of immune genes
using expression data from purified immune cells and
used RNA sequencing data to identify subpopulations of
TILs. Specific TILs were associated with distinct molecu-
lar phenotypes (hypermutated and non-hypermutated
phenotype; MSS and high levels of microsatellite instable
(MSI-H) phenotype; and CpG island methylation (CIMP)
phenotype). Next we used RNA- and whole-exome NGS
data to chart the antigenome comprising two major clas-
ses: cancer-germline antigens and neo-antigens, and could
show that neo-antigens were rarely shared between pa-
tients. We then analyzed the genetic basis of the tu-
mors and revealed distinct tumor escape mechanisms
for the patient subgroups. Finally, we used two modelingapproaches, namely reconstruction of the interaction
network of TILs and immunomodulatory molecules,
and linear regression analyses of the determinants of
immunogenicity, and identified novel candidates for im-
munotherapy. These targets were subsequently validated
using large independent cohorts and an orthologous im-
munodeficient mouse model.
Results
Tumor-infiltrating lymphocyte subpopulations are
associated with distinct molecular phenotypes in
colorectal cancer
An overview of the analytical strategy and the methods
used is shown in Figure S1 in Additional file 1. We first
built a compendium of genes (1,980) related to specific
immune cells using gene expression profiles assessed in
purified immune cells and extracted from 36 studies
comprising 813 microarrays (Figure S2 in Additional file
1; Table S1 in Additional file 2). A subset of these genes
which are representative for specific immune cell sub-
populations were then selected based on correlation ana-
lysis (Table S2 in Additional file 2). In the following we
call these genes immune metagenes (812 in total). The
expression of the immune metagenes as determined by
RNA sequencing was used to estimate 28 subpopula-
tions of TILs, including major types related to adaptive
immunity (central and effector memory CD4+/CD8+
cells, gamma delta T cells (Tgd), T-helper 1 (Th1), Th2,
Th17, regulatory T cells (Treg), follicular helper T cells
(Tfh), immature and memory B cells) as well as innate
immunity (macrophages, monocytes, mast cells, eosino-
phils, neutrophils, dendritic cells (DCs), natural killer
(NK) cells, and natural killer T cells (NKT).
The enrichment analysis of TIL subpopulations using
metagene expression profiles indicated that TILs are
present in 96.6% of the tumors and that 70% of the tu-
mors show a T-cell phenotype (Figure 1A), previously
defined as inflamed phenotype [11]. These results are
consistent with our previous studies [12,13]. The higher
resolution of the analysis in the present study revealed a
comprehensive picture of the intratumoral immune
landscape and showed high enrichment of many sub-
populations of both adaptive and innate immunity. The
adaptive immunity subpopulations with highest enrich-
ments included effector memory CD4+ and CD8+ cells,
immature B cells, and Th1 cells, whereas the innate im-
munity subpopulations included activated DCs, myeloid-
derived suppressor cells (MDSCs) and macrophages
(Figure 1A; see also interactive version at [14]). The
metagene expression signatures were then used to as-
sociate TIL subpopulations with distinct molecular
phenotypes from the TCGA cohort related to the muta-
tional status (hypermutated and non-hypermutatated),
the microsatellite status (MSS and MSI-H), and the
Figure 1 Molecular phenotypes and immunophenotypes of CRC tumors. (A) Subpopulations of TILs enriched in the tumors and spin chart
for the TCGA cohort . The numbers for the subpopulations represent percentages of tumors with enriched immune cell subpopulations. T-cell
compartment includes all T-cell subpopulations. Tem, effector memory T cell; Tcm, central memory T cell; Act, activated; aDC, activated dendritic
cell; pDC, plasmacytoid dendritic cell; iDC, immature dendritic cell; Mac, macrophages; Eos, eosinophils; Neu, neutrophils; NK, natural killer cells.
The spin chart gives an overview of the cohort (n = 460) with each line representing one patient. The molecular phenotypes are shown in the
inner circle. The subpopulations of TILs significantly (q-value ≤0.1) enriched in individual patients based on single sample gene set enrichment
analysis (ssGSEA) are shown in the outer circles. Within each molecular phenotype, the patients are sorted according to the enriched immune cell
types: the immune cell types are ordered by their odds ratio for the corresponding molecular phenotype in a descending order. CIMP-H,
CIMP-high; CIMP-L, CIMP-low; CIMP-Neg, CIMP-negative. (B) Heat map of log-transformed odds ratios of the TIL subpopulations for three different
molecular phenotypes and different combinations thereof (for example, hypermutated, MSI-H, and CIMP-L). (C) Kaplan-Meier (KM) curves for
overall survival for patients using the relative number of immune cells (Tem CD8, Tem CD4, Treg, NK, aDC and MDSC). Shown are groups with
high relative numbers of cells (hi, red) versus the low relative number of cells (lo, blue) at the optimum value cutoff. CI, confidence interval; HR,
hazards ratio.
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negative [15]) (Figure 1A). As can be seen, there is a
partial overlap between the different phenotypes (for ex-
ample, all MSI-H tumors are hypermutated and most of
them belong to the CIMP-high group).The quantification of TIL subpopulations showed that
TILs were associated with distinct molecular phenotypes
related to three features (mutational status, microsatel-
lite status, and methylation status) or combinations
thereof (Figure 1B). It should be noted that from 12
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statuses × 3 methylation subtypes) 5 groups were excluded
due to a small number of samples. As expected, MSI-H
tumors were characterized by enrichment of TILs mostly
related to adaptive immunity. A small group of the hyper-
mutated tumors with MSS phenotype (denoted as MSS^)
were characterized by lower enrichment of effector mem-
ory and central memory CD4+ and CD8+ cells. Interest-
ingly, in the CIMP-high groups the only cell types that
were enriched in MSS tumors but not in MSI-H tumors
were Th17 cells and NKbright cells. Thus, combining
RNA sequencing data and immune metagenes enables
precise molecular taxonomy for any CRC phenotype char-
acterized by genomic instability, mutational load, or epi-
genetic instability.
Immunophenotypes evolve during tumor progression
We have previously shown that individual TIL subpopu-
lations are associated with overall survival (OS) and
disease-free survival (DFS), including CD8+ T cells [12]
and B cells [13]. The present analyses of high-resolution
data (RNA-seq) enabled us for the first time to comprehen-
sively chart the immune landscape and identify the associa-
tions of major TIL subpopulations with OS (Figure 1C;
Figure S3 in Additional file 1). Results of this univariate
analysis were comparable with those of the multivariate
analysis using a Cox regression model for correcting for
the molecular phenotypes (Table S3 in Additional file 2).
This is in concordance with our previous study, which
showed that immune signatures have the highest predict-
ive accuracy [16]. TILs associated with good prognosis in-
cluded effector memory and central memory CD8+ cells,
effector memory CD4+ cells, NK cells, and activated DCs,
whereas MDSCs, Tregs, Th17, and mast cells were associ-
ated with bad prognosis.
Tumor progression is characterized by changes in the
genomic landscape and clonal architecture. In order to
analyze the immune phenotypes during tumor progres-
sion, the examination of early and advanced lesions from
the same patient or matching primary and metastases
would be required. While comparisons across patients
are less robust due to intratumor variations, we attempted
to identify immune subsets during tumor progression
using the TCGA data. We focused on non-hypermutated
tumors (MSS patients) since there were only two MSI-H
and MSS^ patients with stage IV tumors. In the MSS
patients the number of mutations increased during pro-
gression from stage I to stage IV (Figure S4 in Additional
file 1). Intriguingly, the number of subclonal mutations
slightly decreased (P = 0.002, r = -0.16). The progression of
the tumor was characterized by distinct immune patterns.
For example, activated CD8+ cells were significantly
enriched from stage I to stage III tumors and depleted in
stage IV tumors (Figure S4 in Additional file 1). Incontrast, Tregs were depleted in stage I and stage II and
enriched in stage III and stage IV tumors. In general, the
enrichment of the TIL subpopulations related to adaptive
immunity decreased whereas enrichment of TILs related
to innate immunity increased. This was also evident at the
level of individual markers (Figure S5 in Additional file 1).
Colorectal cancer antigenome is diverse and sparse
Comprehensive characterization of the cancer antige-
nome is a prerequisite for developing personalized can-
cer immunotherapies, that is, for selecting antigens for
cancer vaccination. For cancer vaccination two types of
antigens with high tumor specificity can be used: neo-
antigens arising from somatic mutations which are
unique to each tumor and non-mutated cancer-germline
antigens which are shared between many tumors [17].
We therefore characterized both antigen classes in three
patient groups: MSI-H, MSS^, and MSS. RNA-sequencing
data were used to predict at four-digit resolution the
human leukocyte antigen (HLA) haplotype of each pa-
tient and to identify cancer-germline antigens. In order
to identify neo-antigens we used 222,169 somatic muta-
tions from the TCGA cohort, selected expressed muta-
tions (207,679) and evaluated binding of all possible
8- to 11-mer mutant peptides (4,618,035) (Materials
and methods).
A large number of cancer-germline antigens (178)
were detectable in all patients (Figure 2A). About 62%
(110) of the expressed cancer-germline antigens were
shared and only 8% (14) were specific for MSS, MSI-H,
and MSS^ tumors. This intriguing result suggests that
the expression of cancer-germline antigens is independ-
ent of both the molecular phenotype and the immuno-
phenotype of the tumors.
In strong contrast, the neo-antigens were infrequently
shared between patients (Figure 2B). From the total of
92,028 neo-antigens (19,241 for MSS, 42,562 for MSI-H
and 29,717 for MSS^) only 4% (3,714) were shared be-
tween two or more patients (Figure 2B; Table S4 in
Additional file 2). These shared neo-antigens represent
identical peptides originating from one or more genes.
The most frequent neo-antigens were induced by mu-
tations in KRAS, RNF43, and PIK3CA in MSS, MSI-H,
and MSS^ patients and were shared in 7%, 26% and
28% of the patients, respectively. Both, KRAS and
PIK3CA are known to be frequently mutated in CRC.
It was only recently shown that RNF43 is frequently mu-
tated in CRC and endometrial cancers [18]. Peptides for
the neo-antigens that are shared in at least seven patients
and the corresponding genes are given in Figure S6 in
Additional file 1 (see interactive version at [14]). The
number of neo-antigens and the neo-antigen frequen-
cies were 45 ± 22, 635 ± 308, and 1,651 ± 1,455, and
0.38, 0.48, and 0.39 for the MSS, MSI-H, and MSS^
Figure 2 (See legend on next page.)
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Figure 2 CRC antigenome comprising two antigen classes: cancer-germline antigens and neo-antigens. (A) Two-dimensional hierarchical
clustering of the expression of cancer-germline antigens calculated from the RNA sequencing data for the three molecular phenotypes (MSS,
MSI-H and MSS^). All displayed matrix elements met the threshold as described in Methods. Genes marked in bold were significantly higher
expressed in a specific patient group. (B) Two-dimensional hierarchical clustering of neo-antigens, that is, identical peptides shared in more than
two patients in the three groups. Highlighted are most frequent neo-antigens in the specific group and the corresponding mutated gene.
(C) Neo-antigen frequencies from stage I to stage IV in MSS, MSI-H and MSS^ patients. (D) Survival analysis for the number of immunogenic
missense and frameshift mutations in all CRC patients.
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frequencies decreased from 0.43 in stage I to 0.39 in
stage IV (P = 0.05; Figure 2C). Hence, with increasing
tumor stage, tumor antigenicity appears to decrease,
which might explain why prognosis is inversely related
to tumor stage at diagnosis. It can be envisaged that in
stage I there is a greater presence of antigenic tumor
cells and/or that the immune cells are less anergic or
exhausted [19]. Finally, survival analysis showed an asso-
ciation of the number of immunogenic missense and
frameshift mutations with survival (Figure 2D), albeit not
significant.
Genetic basis of the tumors determines tumor escape
mechanisms
Our analysis of the antigenome landscape of CRC dem-
onstrated that the majority of the patients, including pa-
tients with lower mutational load (MSS), express neo-
antigens and, hence, cancer vaccination may be effective
also in these patients. However, tumor mutational het-
erogeneity adds another layer of complexity and may
hinder personalized strategies [20]. Within a tumor,
clones may be present which do not elicit T-cell re-
sponses against a given neo-antigen used in the vaccine
and these cells may thus have selective advantage and
outgrow other clones. Using SNP-array data and whole-
exome NGS data we calculated the cancer cell fractions
and estimated the tumor heterogeneity for MSS and
MSI-H patients. Two different algorithms were applied
for this analysis, ABSOLUTE [21] and PyClone [22],
which led to similar results (data not shown). MSS pa-
tients were then clustered into four groups based on the
cancer cell fractions (Figure S7 in Additional file 1). As ex-
pected, MSI-H tumors were the most heterogeneous ones
and had the highest neo-antigen frequencies (Figure 3A,B).
In the MSS phenotype the most homogeneous tumors
(cluster 1) had the largest neo-antigen frequencies
(Figure 3C). Survival analyses showed that MSS pa-
tients with homogeneous tumors (clusters 1 and 2) had
better prognosis (hazard ratio 0.58, confidence interval
0.3 to 1.12) than the patients with more heterogeneous
tumors (clusters 3 and 4) (Figure 3C).
We then characterized the immunophenotypes for
the genetically different tumors and visualized the
immune subpopulations, which were enriched anddepleted compared with normal tissue, using volcano
plots (Figure 3D). Major differences in the enrichment
of TIL subpopulations could be observed in the MSI-
H, MSS^, and the four MSS subtypes. MSI-H tumors
were enriched with all CD4 and CD8 subpopulations
as well as with activated DCs and NK cells. The im-
mune response was less pronounced in MSS^ tumors,
and was further dampened in the MSS tumors, albeit
all groups were enriched with cytotoxic cells. Interest-
ingly, in the MSS tumors the number of significantly
depleted subpopulations was proportional to the tumor
heterogeneity and increased from cluster 1 to cluster 4
(Figure 3D).
The genetic and immunophenotypic variability of the
CRC tumors shown above impose the question of
whether different tumors use different mechanisms of
tumor escape. This knowledge is of utmost importance
for making decisions about the most appropriate im-
munotherapy regimen. We carried out systematic analysis
of the escape mechanisms and examined the enrichment
of immunosuppressive cell types (MDSCs and Tregs), and
the expression of five classes of molecules: key immunoin-
hibitory genes which may be upregulated to produce
tumor escape (for example, CTLA-4), key immunosti-
mulatory genes (for example, OX40), which may be
downregulated to avoid immune destruction, as well as
major histocompatibility (MHC) class I, MHC class II,
and non-classical MHC molecules. We included all previ-
ously reported immunomodulators [23,24] and the recently
identified candidate STING (stimulator of interferon
genes complex) [25].
In the hypermutated tumors (MSI-H and MSS^) Tregs
and MDSCs were depleted, whereas in the non-
hypermutated tumors (MSS clusters) either Tregs
(cluster 1) or MDSCs (clusters 2 to 4) were enriched
(Figure 3D). The expression profiles of the immuno-
modulatory genes showed consistent upregulation of
CD137L and down regulation of BTLA, CD160, CD27,
TACI, BCMA and IL-6R in all tumors (Figure 3E). In
the hypermutated tumors the immunoinhibitors CTLA4
and IDO1 were highly upregulated whereas PD1 and PD-
L1 were upregulated only in the MSI-H group (Figure 3E;
Figure S8 in Additional file 1). In the non-hypermutated
tumors a number of immunoinhibitors were significantly
downregulated (Figure S8 in Additional file 1). Strikingly,
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Figure 3 Tumor heterogeneity and intratumoral immune landscapes in hypermutated and non-hypermutated tumors. (A) Violin plots
(that is, box plots with a rotated probability density plot) of intratumoral heterogeneity represented by the calculated cancer cell fractions in MSI-H and
MSS patients. MSS tumors (colored plots) were grouped in four clusters based on their cancer cell fraction distributions. The Kolmogorov-Smirnov D
statistic was used as a similarity measure to cluster the tumors into the four groups (Figure S7 in Additional file 1). (B) Number of mutations and
neo-antigen frequencies in the hypermutated tumors (MSI-H and MSS^) and in the four clusters of non-hypermutated tumors (MSS) colored as in
panel (A). * P > 0.01, ** P < 0.01. Error bars represent standard error of the mean. (C) Survival analysis of the homogeneous (cluster1 and cluster2) and
heterogeneous (cluster3 and cluster4) MSS tumors in late stages. (D) Volcano plots for enriched (red) and depleted (blue) TIL subpopulations in the
distinct patient groups compared with normal samples (n = 50). (E) Log2 fold change of the expression (RNA sequencing data) of selected genes
relative to normal tissue for the MSI-H and MSS patients colored as in (A).
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tional to the decreasing expression of many immunomod-
ulators, as well as MHC class I and class II molecules.
Notably, clusters 3 and 4 showed increased expression of
HLA-G molecules, which is associated with worse OS and
DFS in CRC [26]. Thus, it appears that the genetic basis of
the tumors determines the tumor escape mechanisms. In
hypermutated tumors immunoinhibitors are upregulated
and immunosuppressive cells are depleted. In non-
hypermutated tumors (MSS) immunosuppressive cells are
enriched and the immunoinhibitors are downregulated. It
is noteworthy that within the group of non-hypermutated
tumors, the tumor heterogeneity might represent an add-
itional parameter, which can be used to identify the patients
that would benefit from targeted immunotherapy. However,
further validation and functional studies are required to
investigate the predictive power of this parameter.
Reconstruction of the interaction network of TILs and
T-cell immunomodulatory molecules reveals candidates
for immunotherapy
A number of immunoinhibitory and immunostimulatory
molecules are currently under investigation for immuno-
therapy in various cancers [27]. In an attempt to identify
promising candidates for CRC immunotherapy, we re-
constructed a network of TILs and immunomodulatory
molecules for which agonists/antagonists are available.
The interaction network between TILs and these drug-
gable targets was then filtered for molecules which were
significantly associated with good or bad prognosis in
the TCGA data set. The highly interconnected subpopu-
lations of TILs were Tfh, B cells, immature DCs, Tgd,
Tregs, and CD8+ cells (Figure 4A). The molecules sig-
nificantly associated with survival included PD-1 and
PD-L2. To validate the candidates we then collated pub-
lic expression data sets from 11 microarray studies com-
prising a total of 1,945 patients (Table S5 in Additional
file 2). Survival analyses carried out for the nine candi-
dates showed that BCMA (TNFRSF17) was consistently
associated with good prognosis in all cohorts (Figure 4B;
Figure S9 in Additional file 1). BCMA is a member of
the tumor necrosis factor receptor superfamily and was
first described as B-cell maturation factor [28]. The re-
ceptor specifically binds to BAFF (TNFRSF13B) and
leads to the activation of NF-kappa B and MAPK8/JNK
[29]. An antagonist is currently in phase II/III trials for
other indications and in phase I for non-Hodgkin
lymphoma and multiple myeloma [27].
Linear regression modeling identifies major determinants
of tumor immunogenicity in colorectal cancer
Antigenicity of the tumor is necessary but not sufficient
for it to be immunogenic, that is, to elicit adaptive im-
mune responses in vivo. The microenvironment of thetumor can be immunosuppressive and prevent anti-
tumor immunity. Our previous study [13] and the re-
sults of this work show not only highly heterogeneous
TILs but also varying ratios of different T-cell subsets,
including suppressive ones. These observations raise the
question of the underlying molecular mechanisms that
explain the differences in immunogenicity of the tumors.
The question can be reduced to the notion of sources of
immunogenic differences, which can be divided into two
categories: tumor intrinsic factors and tumor extrinsic
factors. Tumor intrinsic factors include the cancer anti-
genome, the expression of immunoinhibitors and immu-
nostimulators (for example, PD-L1 [17]), and HLA class
I molecule alterations [30]. Tumor extrinsic factors in-
clude chemokines which regulate T-cell trafficking [31],
immunosuppressive TILs, soluble immunomodulatory
factors (cytokines) [31], and germline polymorphisms in
immune regulatory genes [32]. We examined major
tumor intrinsic and extrinsic factors in order to compre-
hensively characterize the tumor immunogenicity. A lin-
ear regression model including all determinants (221
parameters; Table S6 in Additional file 2) was applied to
predict the presence of cytotoxic cells (approximated as
the average of the expression levels of the CD8+, NK,
and Tgd cell metagenes). The number of features in the
linear model was reduced by lasso-regularization [33] and
only variables with significant coefficients (P < 0.001) were
included in the final model. The model was evaluated by a
10-fold cross-validation procedure. The identified features
disclosed the major determinants, which were ranked as
follows: MDSCs, Tregs, CD86/B7-2, CCR8, CXCR5, and
PD-L2) (Figure 4C).
All but one of these determinants have been previously
implicated as modulators of the tumor microenviron-
ment. MDCSs and Tregs are well-known immunosup-
pressors [31]. CD86/B7-2 is ligand for CTLA4 whereas
PD-L2 is ligand for PD-1. Clinical trials of blocking
monoclonal antibodies against CTLA4 and PD-1 are
currently underway for a variety of epithelial malignan-
cies, including CRC [34]. CXCR5 is a receptor for the
CXCL13 chemokine, for which we recently showed that
genomic instability is a mechanism associated with intra-
tumoral Tfh and B-cell infiltration in CRC [13]. A novel
candidate identified in the present study was the chemo-
kine receptor CCR8.
We then analyzed the available data and provide here
several lines of evidence for the involvement of CCR8 in
tumor progression in human CRC: 1) CCR8 is downreg-
ulated in metastatic tumors compared with non-
metastatic tumors in the TCGA cohort (Figure 4D); 2)
patients with germline mutations in CCR8 have lower
survival rates, albeit not significant (P = 0.069; Figure 4E);
3) expression of CCR8 in the TCGA cohort was signifi-
cantly associated with good prognosis. We also analyzed
Figure 4 Determinants of tumor immunogenicity in human CRC. (A) Network of TILs and immunomodulatory molecules. Shown are only
candidate genes (hexagons) which were significantly associated with survival in the TCGA cohort. The thickness of the edges is proportional to
the strength of the pairwise gene correlation. The size of the circles (TILs) is inversely proportional to the log-rank P-value, with large circles
representing lower P-values. Significant association with OS is indicated by a blue node border. Bad prognosis is represented by red node color,
good prognosis by green node color. (B) Survival analysis for BCMA using RNA sequencing data (TCGA cohort) as well as microarray data from 11
independent cohorts. OS, overall survival; DFS, disease-free survival. A forest plot with the corresponding hazard ratios is shown on the right. Red
asterisks mark the cohorts for which the results are significant. CI, confidence interval. (C) Table with the major determinants of tumor immunogenicity
identified using linear regression modeling, the corresponding coefficients and the adjusted P-values. Shown are also the results of the survival analysis
for the TCGA cohort, including OS hazard ratio and the P-values. (D) Expression of the chemokine CCR8 in patients with and without metastasis in the
TCGA cohort calculated from the RNA sequencing data. (E) Kaplan-Meier curves for germline mutations in CCR8 for the TCGA cohort. (F) Survival
analysis for CCR8 in the TCGA cohort (RNA sequencing data) and 10 independent cohorts (microarray data). Red asterisks mark the cohorts for which
the results are significant. (G) Hematoxylin and eosin staining of tissue sections from an orthotopic mouse model using murine MC38 cell line in
wild-type C57Bl/6 and immunodeficient RAG1-/- mice. IF, immune cell infiltration; T, tumor. Black bar: 200 μm. (H,I) Endoscopic scoring (H) and tumor
growth (I) after injection of MC38 cells (104) into the submucosa of wild-type C57Bl/6 and RAG1-/- mice. Error bars represent standard error of the
mean. (J) Expression of CCR8 and its ligand CCL1 in the orthotopic mouse model of CRC. * P = 0.038, ** P = 0.017. Error bars represent standard error
of the mean.
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sequencing data from the TCGA cohort as well as using
unpublished quantitative real-time PCR data from our
previous study [35] comprising 125 samples and show
that CCR8, and to lesser extent CCL1, are expressed in
human CRC tissue (Figure S10 in Additional file 1). We
then validated the prognostic power of CCR8 in the
TCGA cohort and 10 additional cohorts (n = 1,862; in
one cohort the probes for CCR8 were not identifiable;
Figure 4F). These results indicate that CCR8 is a novel
candidate for modulating immunogenicity in CRC.
There are conflicting results in the literature on the
expression of CCR8 in various cell types. Originally it
was shown that CCR8 is expressed in Th2 cells and is
involved in eosinophil recruitment [36]. In a recent
study it was reported that CCR8 is expressed in Tregs
[37] whereas another study using a melanoma model re-
ported that CCR8 is expressed on tumor cells [38]. This
study showed that blocking CCR8 or CCL1 inhibits
tumor cell migration to lymphatic endothelial cells and
that CCR8 is also expressed in human metastatic melan-
oma. In order to further elucidate the role of CCR8 in
CRC we used an orthotopic CRC mouse model. Mouse
CRC cell line MC38 was injected endoscopically into the
colonic submucosa of syngenic C57Bl/6 wild-type and
RAG1-/- immunodeficient mice and the tumor growth
was monitored weekly using endoscopy. The morph-
ology of these tumors is comparable to human CRC,
showing infiltrative growth through the mucosa and an
immune response within the tumor and at the tumor
margin (Figure 4G). Tumor growth was monitored by
endoscopy weekly (Figure 4H) and developed faster in
RAG1-/- mice (Figure 4I). The expression of CCR8, and
to lesser extent its ligand CCL1, were very low in immu-
nodeficient RAG1-/- mice (Figure 4J), indicating that
CCR8 is primarily expressed in TILs in CRC.
Discussion
We have developed an integrated strategy and for the
first time characterized the immunophenotypes and the
antigenome of human CRC. Our approach to deeply
mine large datasets enabled us not only to disentangle
tumor-immune cell interactions, but also to devise strat-
egies for cancer immunotherapy in CRC. The dissection
of the complex tumor microenvironment suggests sev-
eral important biological conclusions.
First, the results support the notion that the subpopu-
lations of TILs mirror the underlying molecular pheno-
types. Moreover, based on the enrichment of TIL
subpopulations, specific characterization of all three
studied molecular phenotypes (mutational status, micro-
satellite status, methylation status) or the combinations
thereof is possible. Hence, a single assay (RNA sequen-
cing) enables refined molecular taxonomy of the tumors.One possible explanation for this observation is that the
number of features (expression of several hundred
mRNAs) with cell type-related expression patterns is
two orders of magnitude larger than the features used
for traditional molecular phenotyping. Notably, the use
of well-characterized expression of gene signatures in
pure cell types reduces the noise inherent in high-
throughput expression studies. With the advent of single
cell sequencing techniques [39] and the development of
deconvolution algorithms [40], we expect that future
studies will allow even more precise characterization of
the intratumoral immune landscape. We advocate that
RNA sequencing should be routinely performed on
tumor specimens and might lead to the identification of
additional molecular subtypes.
Second, the antigenicity of the tumors and the intratu-
moral immune landscape evolve in parallel during tumor
progression, with decreasing antigen frequencies, allevi-
ated adaptive immunity response, and intensified innate
immunity. The data also indicate that the mutational
load has a major impact on the number of TILs as ob-
served in the MSI-H and MSS^ groups. In the patient
group with lower mutational load (MSS), it appears that
tumor antigenicity decreases to a larger extent, as shown
by an increasing number of mutations and decreasing
neo-antigen frequencies during tumor progression. It
should be noted that although longitudinal genomic data
are currently not available, the large number of patients
enabled the use of the concept of a statistical ensemble,
that is, averaging large numbers of patients per stage
represents a snap shot of the underlying process.
Third, the results of the quantification of the antige-
nome in CRC showed that the number and expression
levels of cancer-germline antigens were similar across
tumors with different genomic instabilities, mutational
loads, epigenetic instabilities, or TIL enrichments, whereas
the neo-antigen landscape was highly diverse. It is intri-
guing to speculate that the T-cell responses might be pri-
marily directed against neo-antigens rather than against
cancer-germline antigens. It is noteworthy that the quality
of the T-cell responses directed against neo-antigens and
cancer-germline antigens has not been compared so far
and future experimental studies are needed in order to
validate our observation. Such studies would require isola-
tion of neo-antigen and cancer-germline antigen-specific
T cells from patient material and experiments with autolo-
gous tumors.
Finally, one striking observation was how the genetic
basis of the tumors determines the tumor escape mecha-
nisms. As expected, hypermutated tumors (MSI-H and
MSS^ tumors) showed high intratumor heterogeneity,
suggesting that the greater mutational load in these tu-
mors results in a higher load of neo-antigens, and pro-
motes T-cell activation and infiltration [41]. These tumors
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suppressive cells and upregulation of immunoinhibitory
molecules. Interestingly, similar effective immune responses
were observed also in non-hypermutated tumors, but only
in the group of homogeneous tumors. The inverse associ-
ation of the tumor heterogeneity and the immune re-
sponses (and hence, distinct tumor escape mechanisms)
was evident at several levels: enrichment of immunosup-
pressive cells, expression of immunostimulators, and ex-
pression of MHC I and MHC II molecules. One possible
explanation could be that the immune system is able to effi-
ciently sculpt the clonal architecture (immunoediting [42])
only of developing non-hypermutated tumors. However,
the available data do not allow deciphering the cause and
the consequence of this complex tumor-immune cell
interaction, and further studies will be necessary to iden-
tify the mechanisms driving this cancer immunoediting in
tumors with different mutational phenotypes.
Beyond these biological insights, the results from this
study also have important implications for clinical
translations.
Implications for cancer immunotherapies
The results of our systematic analyses of genomic data
have several critical implications for cancer immuno-
therapies in CRC. Most importantly, we propose the use
of two genetic features, that is, mutational load and
tumor heterogeneity, to stratify the patients for targeted
immunotherapy. In our analyses we used whole-exome
NGS and SNP array data to estimate the mutational load
and the tumor heterogeneity. A new algorithm [43] al-
lows the quantification of tumor heterogeneity solely
from whole-exome NGS data and might pave the way
for clinical application. Since many clinical centers are
routinely collecting whole-exome NGS data, our ap-
proach can be used to analyze retrospective cohorts and
initiate prospective studies on cancer immunotherapy of
CRC and other solid tumors.
The set of major determinants of tumor immunogen-
icity in CRC we identified included not only immuno-
suppressive cells and chemokine receptors but also
molecules which are currently tested in clinical trials:
B7-2 (ligand of CTLA4) and PD-L2 (ligand of PD-1). It
will be important to identify predictive markers for these
therapies in order to select the patients most likely to re-
spond to therapy. For example, preliminary evidence for
a correlation between PD-L1 expression on tumor cells
and the likelihood of response to anti-PD-1 therapy was
reported in a patient with CRC [44]. Thus, the use of the
analytical strategy presented here has the potential to pin-
point predictive markers in patients on immunotherapy.
In addition, our integrative analyses led to the identifica-
tion of two novel targets for therapy: BCMA and CCR8.
BCMA was identified using a network reconstructionapproach and validated in 11 independent cohorts. The
function of this receptor is well characterized and both ag-
onists and antagonists are available to study the effects on
tumor progression. CCR8 was identified using a feature
reduction method and the prognostic power was validated
using independent cohorts. The function of the CCR8-
CCL1 axis is less clear. In melanoma CCR8-CCL1 con-
trols the egress of tumor cells from the afferent lymphatics
into the lymph node [38]. Here we show in an orthotopic
mouse model of CRC that CCR8 is not expressed in tu-
mors from RAG1-/- mice, indicating that the expression
is limited to immune cells. Hence, it appears that the func-
tion of CCR8-CCL1 is different in endothelial tumors.
Further experimental studies are required to identify the
role of CCR8 in CRC.
Implications for cancer vaccination
The quantification of the antigenome and both antigen
classes, cancer-germline antigens and neo-antigens, of
CRC has major clinical consequences. The sparsity of
the neo-antigen space suggests that neo-antigens are
rarely shared among patients and advocates against the
development of off-the-shelf vaccines. Based on the re-
sults from our analyses, the size of the peptide library
which could be required for vaccination of 50% of the
MSS patients would be around 70. Paradoxically, it
seems that a patient group with a high mutation rate
(MSI-H) is amenable for off-the shelf vaccination: a vac-
cine with five peptides would cover 50% of these pa-
tients. Thus, personalized cancer vaccination strategy is
required in which whole-exome NGS is performed to
identify somatic mutations, followed by bioinformatics
analyses to identify neo-antigens, and synthesis of
peptide- or DNA/RNA-based vaccines. Viability of such
personalized cancer vaccination strategy was recently
demonstrated in clinical studies in melanoma patients
[7,45]. These proof-of-principle studies provided evi-
dence that T cells reactive to neo-antigens may play a
critical role in tumor regression.
However, patients should be stratified for cancer vac-
cination based on the evaluation of the intratumoral im-
mune landscape rather than on the molecular phenotype
(hypermutated versus non-hypermutated, or MSS versus
MSI-H). As shown in this study, comprehensive cha-
racterization of both the genomic and intratumoral im-
mune landscapes is possible using whole-exome NGS
and RNA sequencing data, and can pave the way to-
wards personalized cancer immunotherapy. Moreover, in
order to increase the likelihood that a neo-antigen vac-
cine will induce T-cell responses and prevent other
clones from outgrowing, multi-epitope vaccines seem
obligatory. It was recently shown that using this type of
multi-epitope vaccine regimen up to 12 peptides can be
used [46]. However, the exact number of candidate
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patient-derived xenograft models. Finally, additional
studies will be needed in order to prioritize antigens
from a large number of candidates and select the opti-
mal set of antigens.
Conclusions
The approach we show here to characterize the immu-
nophenotypes and the antigenomes of tumors using
NGS data can help to identify mechanisms of tumor
progression and disentangle the complex tumor-immune
cell interactions not only in CRC but also in other solid
cancers. Over and above, it can help to improve thera-
peutic efficacy, even in the absence of immunotherapy.
Understanding the molecular basis of the interactions
between cytotoxic chemotherapeutics or targeted anti-
cancer agents and the immune system is essential for
the development of optimal therapeutic schemes [47]
and in the long run will enable precision oncoimmunol-
ogy and result in clinical benefit for the patients.
Materials and methods
Identification of immune-related genes
In order to build a compendium of immune genes re-
lated to specific immune cell subpopulations, we col-
lected expression profiles for different immune cell types
from 36 studies from the Gene Expression Omnibus
[48] and Array Express [49]. The list of datasets is pro-
vided in Table S1 in Additional file 2. Additionally, we
included expression profiles from normal mucosa [50]
and CRC cell lines [13,51] as out-groups. A total of 813
Affymetrix HG-U133A microarrays were then normal-
ized using the frozen robust multiarray analysis (fRMA)
[52]. Transcripts with significant differential expression
across cell subtypes were identified using ANOVA (P < 0.05).
For the remaining genes, we ranked median mRNA ex-
pression levels within each immune cell type from highest
to lowest. A two-fold change cutoff from the highest ex-
pression group to the next highest expression cell type
was considered as a criterion for cell type-specific expres-
sion. For each gene in each cell type, we fixed the median
expression value of the highest group and permuted group
data and then calculated differential expression in the real
data set compared with the permutation sets (10,000 per-
mutations, P < 0.05). The specificity of gene expression re-
lied on the Jensen-Shannon divergence, which is an
entropy-based measure that quantifies the similarity be-
tween a gene expression pattern and another predefined
pattern that represented an extreme case in which a gene
is expressed in only one tissue [53]. Due to the lack of ex-
pression data, candidate genes for MDSCs were selected
from the literature. The so-defined immune-related gene
expression signatures comprised 1,980 genes. For the
identification of subsets of genes representative forspecific immune cell types, we applied a strategy used in
our previous study [54] and in another published work
[55]: we selected genes with an average correlation r ≥ 0.6
(P < 0.01) between all specific immune genes in the same
cell type [56]. This threshold was chosen to satisfy two
goals: selection of genes with relatively high correlation
such that their correlation could not be considered a
chance event; and selection of a reasonable number of
genes suitable for gene set enrichment analysis (GSEA)
[57] (at least 11 genes per subpopulation). Furthermore,
using a set of genes instead of individual markers for spe-
cific TILs ensures robust estimation and is less susceptible
to noise arising from the expression of the metagenes in
tumor or stromal cells. The immune metagenes (812) are
listed in Table S2 in Additional file 2.
Genomic and clinical data
TCGA Data Portal was queried for clinical information
(n = 610), somatic mutations (n = 522), germline muta-
tions (n = 468), methylation data (n = 582), SNP arrays
(n = 573), and RNA-seq expression profiles (n = 598) of
colon and rectum adenocarcinoma patients (last update
July 2014). Raw sequencing data and alignments were
downloaded from the Cancer Genomics Hub (cgHub)
repository (September 2013). Details on data generation
are available in the original study [10]. A total of 222,169
somatic mutations were screened for potential mutated
epitopes in 522 patients. The mutations were collected
from TCGA portal (n = 386 in the original publication)
and additional experimentally validated somatic muta-
tions (n = 136) were used. The latter were lifted over
from the hg18 to hg19 genome version prior to merging.
To select for germline mutations, all protected muta-
tions were downloaded from TCGA portal. There were
hg19-mapped mutations for 385 tumors, 86 of which
were excluded, because only the somatic mutations were
analyzed. Additional mutations located on the hg18 gen-
ome (n = 169) were lifted over to hg19 prior to merging,
summing up to 468 patients. The normalized gene ex-
pression results analyzed according to the RNASeqV2
protocol were obtained from TCGA portal. Clinical data
and microarray expression profiles for validation were
collated from 11 studies (Gene Expression Omnibus
accession numbers GSE12945, GSE41258, GSE14333,
GSE17538, GSE29623, GSE33113, GSE39582, GSE24549,
GSE24550, GSE30378, GSE28722).
Identification of tumor-infiltrating lymphocyte
subpopulations
We used GSEA [57] to identify immune cell types that
are over-represented in the tumor microenvironment.
The expression levels of each gene were z-score normal-
ized across all patients. For each patient (or group of
patients) genes were then ranked in descending order
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ciation was represented by a normalized enrichment
score (NES). An immune cell type was considered
enriched in a patient or group of patients when the false
discovery rate (q-value) was ≤10%. The tumors were
grouped into seven classes of molecular phenotypes
based on their mutation rates, and CIMP and MSI sta-
tus. Each phenotype class of patients was compared with
the remaining patients to test if there is a nonrandom
association between the phenotype classes and enrich-
ment of an immune cell type (Fisher exact test). The
resulting log-transformed odds ratio was used to cluster
the phenotype classes and the immune cell types (two-
dimensional hierarchical clustering, Euclidean distance,
average linkage). Clustering and visualization were done
with the software Genesis [58]. The relative number of
immune cells, Ic, which is proportional to the absolute
number of cells of a specific immune cell type c in a het-
erogeneous tumor sample, was estimated by calculating
in each cell type:
Ic ¼
Xnc
i¼1
log10 x
c
i þ 1
 
wci
;
where nc is the number of immune metagenes per cell
type c, xci are the normalized counts per gene i (TPM),
and wci is the weight defined as median log2-intensity of
gene i in cell type c from microarray expression data,
which was used to identify immune related genes.
Characterization of colorectal cancer cancer-germline
antigens
The CTDatabase [59] was queried for tumor-specific an-
tigens: 92 localized on chromosome X and 124 in the
remaining chromosomes. The genes that showed down-
regulation in the tumor samples compared with normal
tissue (n = 50) were removed (both from TCGA and
Genentech cohort, statistical significance by at least one
of the EBSeq and DESeq analyses). Using the normal tis-
sue samples, a baseline for cancer-germline antigen ex-
pression was set as three standard deviations from the
median normal expression [60]. Positive expression is
considered above the baseline. Additionally, zero stand-
ard deviation was excluded, resulting with 178 cancer-
germline antigens. K-means clustering was applied to
the RNA-sequencing data for each patient group to
identify clusters of highly expressed cancer-germline
antigens.
Characterization of the molecular phenotypes from TCGA
data
Molecular phenotypes were defined using three features:
MSI status, mutation rates, and methylation subtypes.
For all three molecular phenotypes we used the mostrecent update of the raw sequencing TCGA data set.
The MSI status was experimentally determined and pro-
vided with the clinical dataset (n = 590). The tumors
assigned with MSI-low status (n = 93) were subsumed to
the MSS group (n = 427). In the original publication,
mutation rates were provided for 224 tumors [10].
Adopting the same approach, mutation rates were then
calculated for a total of 470 patients using raw exome-
sequencing data and MSI status as available by the time
of query. To define the hypermutability of the tumors,
we calculated the non-silent mutation rate and the num-
ber of nonsynonymous coding mutations per 1 million
bases and normalized by the sequencing coverage of the
experiment. The mutation rate threshold used to separ-
ate the hypermutated and non-hypermutated tumors
was 8.24 (as reported in [10]). One tumor was excluded,
since it was classified as non-hypermutated with high
microsatellite instability, which could be explained by
potential low purity of the sample. Among the 18 MSS^,
3 were MSI-low, and 15 were MSS. Methylation sub-
types were calculated according to the originally re-
ported workflow: unsupervised hierarchical clustering
(recursively partitioned mixture model) of the highest
deviating DNA methylation measurements [10]. A total
of 582 tumors were classified into three groups: CIMP-
high, CIMP-low and CIMP-negative.
Characterization of colorectal cancer neo-antigens
From the 222,169 somatic mutations, we selected muta-
tions that reside within exons and do not span exon bor-
ders. The DNA changes were mapped on the protein
level. Start codon changes and splicing mutations were
excluded. Along the missense, nonstop, frameshift, and
non-frameshift mutations, we slid windows with lengths
8 of 11 nucleotides. To estimate the HLA haplotype of
each patient, the raw RNA-seq data were analyzed using
HLAminer’s method for prediction of HLA class I alleles
[61]. The HLA sequences were updated according to the
IMGT/HLA public repository [62]. To reduce the ambi-
guity, we considered the matching normal samples, the
Allele Frequency Net Database [63] and the prediction
scores. The predicted four-digit HLA class I alleles and
the mutated peptides were used as input for netMHC-
pan [64] to estimate their binding affinities. Both strong
and weak binding peptides were analyzed for the selec-
tion of neo-antigens (prediction rank ≤2). The selected
neo-antigens were then compared with human protein
sequences and the matching peptides were distinguished
from the novel peptides.
Epitope databases were screened in order to evaluate
the predicted neo-antigens (last update Dec 2014). De-
posited peptidic epitopes, T-cell assays and MHC ligand
assays were downloaded from the Immune Epitope
Database [65], Dana Farber repository [66], and CIG-DB
Angelova et al. Genome Biology  (2015) 16:64 Page 14 of 17[67]. Automatized HTTP-mediated download and HTML
processing retrieved all records from the following data-
bases: MHCBN [68], PeptideDatabase [69], SYFPEITHI
[70], and TANTIGEN [71]. The entries were filtered to se-
lect for HLA class I-binding epitopes. The total number of
reported peptide-MHC affinities (55,000) was five times
smaller than the predicted CRC antigenome, and therefore
only a small fraction of the MHC-peptide combinations
were experimentally covered. Only 15 peptide-HLA allele
or peptide-HLA supertype combinations matched the da-
tabases and 13 of them were experimentally confirmed
(exact peptide-MHC allele matches: VVGAVGVGK and
HLA-A*11:01, CLLDILDTAGL and HLA-A*02:01, and
LLGRNSFEVCV and HLA-A*02:01).
Estimation of tumor heterogeneity
The ABSOLUTE algorithm [21] was used to integrate
the copy number data together with the somatic muta-
tions in order to estimate the purity and ploidy, and meas-
ure the fraction of cancer cells per mutation. The SNP
data were downloaded from TCGA portal and analyzed
with HAPSEG [72]. The cancer cell fractions were also es-
timated using another analysis workflow based on
PyClone [22]. Matched tumor and normal arrays were an-
alyzed together to determine the parent specific DNA
copy numbers [73]. Finally, PyClone v0.12.7 was run with
default parameters. The tumor heterogeneity was then es-
timated as the area under the curve of the cumulative
density function from all cancer cell fractions per tumor.
The clonal architecture of the tumors was compared in a
pairwise manner. A similarity measure was defined as the
Kolmogorov-Smirnov D statistic of the cancer cell fraction
distributions. Based on this measure, four clonal groups
were defined by hierarchical clustering with Euclidean
measure and the Ward agglomeration method.
Reconstruction of the tumor-infiltrating lymphocyte
interaction network
Based on the gene expression data we reconstructed an
immune cell-gene (immunostimulatory/immunoinhibi-
tory molecules) network. The edge weights of the net-
work are based on the Pearson correlation coefficient
between the relative number of immune cells and the
expression of the immunomodulatory molecules (r ≥ 0.6,
P < 0.05). Patients were dichotomized based on the me-
dian relative number of immune cells and the gene ex-
pression of immunomodulator molecules based on
optimal cutoff method, respectively. The nodes of the
network were colored according to the hazard ratio for
OS and marked with a blue border if genes or cell types
were significantly (log-rank) associated with OS. The
size of the immune cell nodes was encoded by -log10
(log rank P-value). The network was visualized using
Cytoscape [74].Identification of determinants of tumor immunogenicity
A linear regression model with 221 parameters including
the neo-antigen frequencies, immunomodulatory factors,
classical and non-classical HLA class I molecule, chemo-
kines, cytokines, immunosuppressive TILs, and cancer-
germline antigens was applied to predict the presence of
cytotoxic cells (as an approximation the average of gene
expression levels of the CD8, NK, and Tgd metagenes
were used). The number of features included in the lin-
ear model was reduced by lasso regularization [33].
Only variables with highly significant coefficients (ad-
justed P < 0.005) were included in the final model. The
model performance was then evaluated by a 10-fold
cross-validation procedure.
Statistical analyses
To test for differential expression across two (tumor and
normal) or more groups (adaptive clusters), we used the
EBSeq [75] and DESeq [76] R packages. The number of
iterations for EBSeq was adjusted to meet the conver-
gence criteria. The number of subclonal mutations was
compared between two or more patient groups using
the Wilcoxon, Mann-Whitney and the Kruskal-Wallis
tests. For multiple comparisons of expression values, neo-
antigen frequencies, and tumor heterogeneity among pa-
tient groups, ANOVA and Tukey post hoc tests were used.
Normality of the distributions was tested with Shapiro-
Wilk test. The information on all follow-ups for each pa-
tient was extracted from the clinical XML files in the
complete clinical set. The overall survival time was de-
fined using the latest information. For survival analysis,
the patients were dichotomized based on gene expression
levels. The optimal cutpoints were searched within the
inner 80% selection interval and chosen based on a min-
imal corrected P-value as proposed by Altman et al. [77]
and based on a maximum Harrell's C indices [78].
Kaplan-Meier estimator of survival was used to visualize
the survival curves. To test whether the number of im-
munogenic mutations (frameshift or missense) correlates
with patient survival, we defined the patients based on the
median value after excluding the outer 20%. Hazard ratio
and the logrank test were used to compare disease-free
and OS between patients in different groups. OS of the
patient groups with different immune cell infiltrations
were additionally analyzed using univariate and multivari-
ate cox regression including MSI status, hypermutation,
methylation subtype, and tumor site (left and right sided)
as binary covariates. All analyses were performed using
the statistical software environment R (package survival).
Mouse model
All animal experiments were performed according to
national guidelines and approved by the government of
Middle Franconia, Germany. C57Bl/6 wild-type and
Angelova et al. Genome Biology  (2015) 16:64 Page 15 of 17Rag1-/- mice were kept on a 12-h light/12-h dark cycle
and housed according to institutional guidelines. Endo-
scopic injection of murine MC38 colon tumor cells in
the submucosa of the colon of the wild-type and
RAG1-/- mice: the needle was positioned inside the
working channel of the endoscope so that there would
be no damage to the colonic mucosa. After insertion of
the endoscope, the tip of the needle was carefully inserted
through the mucosa into the submucosa, and a low num-
ber of cells (104 to 105) were injected into the submucosa.
During subsequent weeks, tumor growth was analyzed via
colon endoscopy. After 2 to 4 weeks, the mice were sacri-
ficed and the tumors excised.
Quantitative real-time PCR
Total RNA was isolated from excised tumors (see mouse
model above) using Trizol™ (Life Technologies, Carlsbad,
CA, USA) and reverse transcribed using SuperScript III
and Random Priming (Life Technologies). SYBR green-based
quantitative PCR was performed on a Viia 7 Lightcycler
(Life Technologies) with the following primers: TfIIb_for-
ward, 5’-GTCACATGTCCGAATCATCCA; TfIIb_reverse,
5’-TCAATAACTCGGTCCCCTACAA; Uxt_forward, 5’-
CTCACAGAGCTCAGCGACAGC; Uxt_reverse, 5’-AA
ATTCTGCAGGCCTTGTAGTTCTC; Ccr8_forward, 5’-C
TTGTTTGTGCTGGGCCTTC; Ccr8_reverse, 5’-GGCCA
GAGACCACCTTACAC; Ccl1_forward, 5’-GGCTGCCGT
GTGGATACAG; Ccl1_reverse, 5’-AGGTGATTTTGAAC
CCACGTTT. Ccl1 and Ccr8 values were normalized
against TfIIb and Uxt.Additional files
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